Quantitative assessment revealed that CD8+ T cell depletion reduced CY12-RP2 efficacy by 41.8% and 25.8% in two independent tumor models, with tumor inhibition declining from 63.2% to 36.8% and from 80.5% to 59.7%, respectively (both p < 0.001) (Figures 6D, E). Here, CD8A is linked to neoplasm.